Iovance Biotherapeutics Appoints Timothy Morris as Chief Financial Officer
August 08 2017 - 4:01PM
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology
company developing novel cancer immunotherapies based on
tumor-infiltrating lymphocyte (TIL) technology, today announced the
appointment of Timothy E. Morris as Chief Financial Officer of the
company, effective August 14, 2017. Mr. Morris has over 30 years of
strategic financial and operating experience in the biotechnology
sector.
“We are very pleased to welcome Tim as CFO of Iovance during
this time of rapid growth for the company,” said Maria Fardis,
Ph.D., MBA, Chief Executive Officer of Iovance Biotherapeutics.
“Tim has an impressive background and brings a wealth of financial
and operational experience having held CFO positions for several
publicly traded biotechnology companies over the past 22 years. In
his prior roles, Tim was instrumental in raising approximately $1
billion in capital to support the ongoing development and
commercial launch of multiple products. I look forward to working
with him to advance the global development of our robust
immuno-oncology pipeline based on our TIL technology.”
Prior to joining Iovance, Mr. Morris was most recently chief
financial officer and head of business development for AcelRx
Pharmaceuticals. Before that, Mr. Morris held the positions of
chief financial officer and global head of corporate development at
VIVUS, Inc. and chief financial officer and senior vice president
of finance, administration and manufacturing at Questcor
Pharmaceuticals, both specialty pharmaceutical companies. He has
extensive deal experience, having completed over 70 corporate
transactions with a combined value in excess of $2.0 billion. Mr.
Morris is a Certified Public Accountant, and holds a B.S. degree
with an emphasis in accounting from California State University at
Chico.
“I am honored to join Maria and the team at Iovance at this
important juncture in the company’s history,” stated Timothy
Morris. “Iovance has a unique immuno-oncology approach to treat
solid tumors. I look forward to utilizing my past experiences to
rapidly advance the company’s robust TIL technology pipeline and
prepare for the commercialization of these therapies, which I
believe can provide benefit to cancer patients worldwide.”
About Iovance Biotherapeutics, Inc. Iovance
Biotherapeutics, Inc. is a clinical-stage biotechnology company
focused on the development of cancer immunotherapy products for the
treatment of various cancers. The Company's lead product candidate
is an adoptive cell therapy using tumor-infiltrating lymphocyte
(TIL) technology being investigated for the treatment of patients
with metastatic melanoma, recurrent and/or metastatic squamous cell
carcinoma of the head and neck and recurrent and metastatic or
persistent cervical cancer. For more information, please
visit http://www.iovance.com.
Forward-Looking Statements Certain matters
discussed in this press release are “forward-looking statements”.
The Company may, in some cases, use terms such as “predicts,”
“believes,” “potential,” “continue,” “estimates,” “anticipates,”
“expects,” “plans,” “intends,” “may,” “could,” “might,” “will,”
“should” or other words that convey uncertainty of future events or
outcomes to identify these forward-looking statements. The
forward-looking statements include risks and uncertainties,
relating to the Company’s ability to advance its global development
programs and the efficacy of its immune-oncology TIL therapies.
A further list and description of the Company’s risks,
uncertainties and other factors can be found in the Company’s most
recent Annual Report on Form 10-K and the Company's subsequent
filings with the Securities and Exchange Commission. Copies of
these filings are available online at www.sec.gov or
http://www.iovance.com. The forward-looking statements are made
only as of the date of this press release and the Company
undertakes no obligation to publicly update such forward-looking
statements to reflect subsequent events or circumstance.
Investor Relations Contact:
Sarah McCabe
Stern Investor Relations, Inc.
212-362-1200
sarah@sternir.com
Media Relations Contact:
Evan Smith/Kotaro Yoshida
FTI Consulting
212-850-5622/212-850-5690
evan.smith@fticonsulting.com
kotaro.yoshida@fticonsulting.com
Iovance Biotherapeutics (NASDAQ:IOVA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Iovance Biotherapeutics (NASDAQ:IOVA)
Historical Stock Chart
From Apr 2023 to Apr 2024